CN1939540A - 含有胰岛素增敏剂和b族维生素的药物组合物 - Google Patents
含有胰岛素增敏剂和b族维生素的药物组合物 Download PDFInfo
- Publication number
- CN1939540A CN1939540A CNA2005101065536A CN200510106553A CN1939540A CN 1939540 A CN1939540 A CN 1939540A CN A2005101065536 A CNA2005101065536 A CN A2005101065536A CN 200510106553 A CN200510106553 A CN 200510106553A CN 1939540 A CN1939540 A CN 1939540A
- Authority
- CN
- China
- Prior art keywords
- group
- diabetes
- rosiglitazone
- pioglitazone
- folic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 12
- 102000004877 Insulin Human genes 0.000 title claims description 6
- 108090001061 Insulin Proteins 0.000 title claims description 6
- 229940125396 insulin Drugs 0.000 title claims description 5
- 102000040350 B family Human genes 0.000 title abstract 2
- 108091072128 B family Proteins 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 89
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 7
- 229930003231 vitamin Natural products 0.000 claims abstract 2
- 235000013343 vitamin Nutrition 0.000 claims abstract 2
- 239000011782 vitamin Substances 0.000 claims abstract 2
- 229940088594 vitamin Drugs 0.000 claims abstract 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 176
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 168
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 162
- 229960004586 rosiglitazone Drugs 0.000 claims description 88
- 229960005095 pioglitazone Drugs 0.000 claims description 84
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 81
- 229960000304 folic acid Drugs 0.000 claims description 81
- 235000019152 folic acid Nutrition 0.000 claims description 81
- 239000011724 folic acid Substances 0.000 claims description 81
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000001610 euglycemic effect Effects 0.000 claims description 21
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 21
- 229960004346 glimepiride Drugs 0.000 claims description 21
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 claims description 19
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims description 18
- 229960002827 pioglitazone hydrochloride Drugs 0.000 claims description 18
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 16
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 15
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 15
- 235000019158 vitamin B6 Nutrition 0.000 claims description 15
- 239000011726 vitamin B6 Substances 0.000 claims description 15
- 229940011671 vitamin b6 Drugs 0.000 claims description 15
- -1 Netolitazone Chemical compound 0.000 claims description 14
- 229930003779 Vitamin B12 Natural products 0.000 claims description 14
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 14
- 235000019163 vitamin B12 Nutrition 0.000 claims description 14
- 239000011715 vitamin B12 Substances 0.000 claims description 14
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 12
- 229930003270 Vitamin B Natural products 0.000 claims description 12
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 12
- 235000019156 vitamin B Nutrition 0.000 claims description 12
- 239000011720 vitamin B Substances 0.000 claims description 12
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 208000002249 Diabetes Complications Diseases 0.000 claims description 10
- 206010012655 Diabetic complications Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 229960003271 rosiglitazone maleate Drugs 0.000 claims description 8
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims description 8
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 claims description 7
- 229960002354 repaglinide Drugs 0.000 claims description 7
- 229960001641 troglitazone Drugs 0.000 claims description 6
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 6
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 6
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 5
- 229950009226 ciglitazone Drugs 0.000 claims description 5
- 229950002375 englitazone Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- PCAZCAZVHLGDBA-UHFFFAOYSA-N 5-[[4-(2-indol-1-ylethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2C=C1 PCAZCAZVHLGDBA-UHFFFAOYSA-N 0.000 claims description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 229950010663 balaglitazone Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- FTRMOJIRMFXZJV-UHFFFAOYSA-N n-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]-1-phenylcyclopropane-1-carboxamide Chemical compound C1CC1(C=1C=CC=CC=1)C(=O)NC(C=C1)=CC=C1CC1SC(=O)NC1=O FTRMOJIRMFXZJV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims description 3
- 229940100389 Sulfonylurea Drugs 0.000 claims description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 3
- 150000004283 biguanides Chemical class 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 229950004994 meglitinide Drugs 0.000 claims description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 3
- RDGUFKZGMLPVHL-QFIPXVFZSA-N (2s)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-(propylamino)propanoic acid Chemical compound C1=CC(C[C@H](NCCC)C(O)=O)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 RDGUFKZGMLPVHL-QFIPXVFZSA-N 0.000 claims description 2
- 241000218176 Corydalis Species 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 206010012665 Diabetic gangrene Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 208000025157 Oral disease Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000001856 erectile effect Effects 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 208000030194 mouth disease Diseases 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 125
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 60
- 210000002700 urine Anatomy 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 46
- 239000008280 blood Substances 0.000 description 46
- 125000003929 folic acid group Chemical group 0.000 description 46
- 229920002472 Starch Polymers 0.000 description 36
- 239000008107 starch Substances 0.000 description 36
- 235000019698 starch Nutrition 0.000 description 36
- 102000002045 Endothelin Human genes 0.000 description 34
- 108050009340 Endothelin Proteins 0.000 description 34
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 32
- 102000019197 Superoxide Dismutase Human genes 0.000 description 30
- 108010012715 Superoxide dismutase Proteins 0.000 description 30
- 235000000346 sugar Nutrition 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 27
- 239000008103 glucose Substances 0.000 description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- 230000003907 kidney function Effects 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- 230000001681 protective effect Effects 0.000 description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 16
- 239000008108 microcrystalline cellulose Substances 0.000 description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 description 16
- 230000003915 cell function Effects 0.000 description 14
- 230000003859 lipid peroxidation Effects 0.000 description 14
- 210000004927 skin cell Anatomy 0.000 description 14
- 239000002002 slurry Substances 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000003449 preventive effect Effects 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000010241 blood sampling Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000004279 orbit Anatomy 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 6
- 230000003035 anti-peroxidant effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000008753 endothelial function Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940035750 glimepiride and pioglitazone Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 229940127017 oral antidiabetic Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | FBG(mmol/L) | ||
给药前 | 第4周 | 第8周 | ||
正常组模型组罗格列酮叶酸罗格列酮+叶酸 | NSNS0.40.080.4+0.08 | 4.9±0.520.4±5.420.1±3.621.4±5.121.4±4.2 | 5.0±0.620.2±3.913.3±5.3**22.3±4.011.2±3.6** | 5.1±1.122.0±3.112.6±2.9**20.4±3.513.8±4.2** |
组别 | 剂量(g/kg) | 尿微量白蛋白(μg/24h) | 尿α1-微球蛋白(μg/24h) |
正常组模型组罗格列酮叶酸罗格列酮+叶酸 | NSNS0.40.080.4+0.08 | 14.3±3.6207.1±58.9(100%)137.7±41.6**(66.5%)168.5±63.2(81.4%)108.2±31.3**(52.2%) | 11.5±2.5166.6±55.1(100%)124.6±38.4**(74.8%)149.3±36.7(89.6%)95.3±24.6**#(57.2%) |
组别 | 剂量(g/kg) | ET(pg/ml) | NO(μmol/L) | SOD(NU/ml) | MDA(nmol/ml) |
正常组模型组罗格列酮叶酸罗格列酮+叶酸 | NSNS0.40.080.4+0.08 | 105.7±25.4183.6±47.7167.1±31.9151.2±14.7**137.1±29.9**# | 82.9±19.858.6±16.560.2±13.571.5±28.675.8±15.6**# | 171.8±15.4134.8±23.8143.1±16.2160.9±21.7170.5±33.8**# | 10.8±1.342.8±14.635.7±7.530.7±13.026.6±6.2**## |
组别 | 剂量(mg/kg) | FBG(mmol/L) | ||
给药前 | 第4周 | 第8周 | ||
正常组模型组吡格列酮叶酸吡格列酮+叶酸 | NSNS30.53+0.04 | 6.3±1.317.5±3.818.0±4.117.0±3.316.5±3.7 | 5.8±1.215.6±2.811.3±3.8**18.6±4.610.8±2.7 | 6.2±1.316.2±4.210.6±1.9**16.7±4.211.7±3.3 |
吡格列酮+叶酸 | 3+0.5 | 16.8±4.0 | 9.7±2.7** | 11.2±3.2** |
组别 | 剂量(g/kg) | 尿微量白蛋白(μg/24h) | 尿α1-微球蛋白(μg/24h) |
正常组模型组吡格列酮叶酸吡格列酮+叶酸吡格列酮+叶酸 | NSNS30.53+0.043+0.5 | 44.8±16.8168.4±44.6114.5±38.3**155.2±43.188.2±31.3**80.8±25.6**# | 37.7±14.3146.9±35.4101.8±30.2**130.6±36.280.2±22.6**#74.2±20.4**# |
组别 | 剂量(g/kg) | ET(pg/ml) | NO(μmol/L) | SOD(NU/ml) | MDA(nmol/ml) |
正常组模型组吡格列酮叶酸吡格列酮+叶酸 | NSNS30.53+0.04 | 225.4±44.8332.4±54.5307.0±41.6289.6±64.4265.4±49.9** | 113.4±24.670.4±20.468.6±24.380.3±30.490.8±25.4**# | 145.6±20.3103.7±20.4110.5±18.6115.4±20.3133.6±24.6**# | 20.7±3.754.9±15.450.4±12.344.3±10.940.8±9.4**# |
吡格列酮+叶酸 | 3+0.5 | 267.6±33.8**# | 88.4±19.4**# | 129.4±30.8**# | 40.6±8.3**# |
组别 | 剂量(mg/kg) | FBG(mmol/L) | ||
给药前 | 第4周 | 第8周 | ||
正常组模型组吡格列酮格列美脲叶酸吡格列酮+叶酸吡格列酮+叶酸+格列美脲 | NSNS1.50.20.11.5+0.11.5+0.1+0.2 | 4.8±0.619.0±4.220.3±3.418.8±4.020.1±4.321.0±3.320.9±4.4 | 5.2±0.920.3±3.315.4±2.6**13.3±3.0**19.6±2.814.8±3.68.4±2.5**## | 4.7±1.218.9±3.714.7±2.8**15.4±4.1**19.9±4.715.2±2.99.2±3.0**## |
组别 | 剂量(g/kg) | 尿微量白蛋白(μg/24h) | 尿α1-微球蛋白(μg/24h) |
正常组模型组吡格列酮格列美脲叶酸吡格列酮+叶酸吡格列酮+叶酸+格列美脲 | NSNS1.50.20.11.5+0.11.5+0.1+0.2 | 30.9±12.9238.3±51.4203.8±43.5196.6±43.6*205.6±30.3166.5±28.9**138.9±24.9**## | 27.6±10.1206.7±45.6188.8±30.6168.3±30.1*180.6±26.8150.5±29.0**120.8±25.6**# |
组别 | 剂量(g/kg) | ET(pg/ml) | NO(μmol/L) | SOD(NU/ml) | MDA(nmol/ml) |
正常组模型组吡格列酮格列美脲叶酸吡格列酮+叶酸吡格列酮+叶酸+格列美脲 | NSNS1.50.20.11.5+0.11.5+0.1+0.2 | 145.8±30.3288.7±50.3257.0±31.6248.8±50.3250.8±44.0235.6±33.9**207.6±30.8**# | 93.8±20.553.9±13.764.8±20.170.3±18.570.3±14.580.8±15.6*88.2±14.6** | 120.3±13.579.6±14.884.4±18.388.3±17.590.7±17.6100.2±20.4**109.4±30.8** | 31.6±8.286.8±13.682.5±15.573.4±10.974.9±14.965.8±9.4**50.8±9.7**# |
并发症 | 对照组(335例)(罗格列酮4~8mg) | 治疗组(371例)(罗格列酮4~8mg+叶酸0.4~0.8mg) |
高血压病脑血管病冠心病糖尿病肾病视网膜病变周围神经病变下肢血管病变 | 71(21.2%)35(10.4%)42(12.5%)73(21.8%)70(20.9%)85(25.4%)16(4.8%) | 62(16.7%)*28(7.55%)43(11.6%)60(16.2%)*66(17.8%)*53(14.3%)*13(3.5%) |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101065536A CN1939540B (zh) | 2005-10-01 | 2005-10-01 | 含有胰岛素增敏剂和b族维生素的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101065536A CN1939540B (zh) | 2005-10-01 | 2005-10-01 | 含有胰岛素增敏剂和b族维生素的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1939540A true CN1939540A (zh) | 2007-04-04 |
CN1939540B CN1939540B (zh) | 2011-07-06 |
Family
ID=37958238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101065536A Active CN1939540B (zh) | 2005-10-01 | 2005-10-01 | 含有胰岛素增敏剂和b族维生素的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1939540B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101897696A (zh) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | 降糖药物组合物及其用途 |
CN103393686A (zh) * | 2013-07-15 | 2013-11-20 | 深圳奥萨医药有限公司 | 噻唑烷二酮类药物与5-甲基四氢叶酸药物组合物的新用途 |
CN103599540A (zh) * | 2013-11-15 | 2014-02-26 | 深圳奥萨医药有限公司 | 含有格列奈类药物和b族维生素的药物组合物及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
-
2005
- 2005-10-01 CN CN2005101065536A patent/CN1939540B/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101897696A (zh) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | 降糖药物组合物及其用途 |
CN101897696B (zh) * | 2009-05-27 | 2014-06-18 | 北京奥萨医药研究中心有限公司 | 降糖药物组合物及其用途 |
CN103393686A (zh) * | 2013-07-15 | 2013-11-20 | 深圳奥萨医药有限公司 | 噻唑烷二酮类药物与5-甲基四氢叶酸药物组合物的新用途 |
CN103393686B (zh) * | 2013-07-15 | 2016-02-17 | 深圳奥萨医药有限公司 | 噻唑烷二酮类药物与5-甲基四氢叶酸药物组合物的用途 |
CN103599540A (zh) * | 2013-11-15 | 2014-02-26 | 深圳奥萨医药有限公司 | 含有格列奈类药物和b族维生素的药物组合物及其用途 |
CN103599540B (zh) * | 2013-11-15 | 2016-09-14 | 深圳奥萨医药有限公司 | 含有格列奈类药物和b族维生素的药物组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1939540B (zh) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1212117C (zh) | 用于治疗糖尿病的药物组合物 | |
TWI278312B (en) | Pharmaceutical composition for treating diabetes or a disease or condition associated with diabetes | |
CN1891229A (zh) | 预防或治疗代谢综合征的药物制剂 | |
CN1446084A (zh) | 胰岛素抗性综合症的治疗 | |
CN1103590C (zh) | 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作 | |
CN1839815A (zh) | 一种含有咖啡酰奎宁酸的药物组合物 | |
CN104349790A (zh) | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 | |
CN1895256A (zh) | 20(s)-原人参二醇在制备抗抑郁药物中的应用 | |
CN1631247A (zh) | 一种耐缺氧抗疲劳的保健食品及其制备工艺 | |
CN1939540A (zh) | 含有胰岛素增敏剂和b族维生素的药物组合物 | |
CN1917895A (zh) | 鱼腥草和插田泡的提取物及其用于预防和治疗过敏性疾病的组合物 | |
CN102727894B (zh) | 一种治疗糖尿病及其并发症的药物组合物及其应用 | |
CN1751693A (zh) | 黄芪多糖在治疗或预防胰岛素抵抗的药中应用 | |
CN103417971A (zh) | 二肽基肽酶抑制剂和b族维生素的药物组合物及用途 | |
CN1265793C (zh) | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 | |
CN1823795A (zh) | 一种治疗糖尿病的药物组合物及其制备方法 | |
CN106554402A (zh) | 一种有降血糖和抗氧化应激作用的新型肽 | |
Badyal et al. | Sitagliptin: a new class of oral drug for type 2 diabetes | |
CN1520818A (zh) | 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物 | |
CN101045076A (zh) | 柿叶乙酸乙酯提取物用于预防和/或治疗糖脂代谢相关疾病 | |
CN1602945A (zh) | 通窍鼻炎软胶囊及其制备工艺 | |
CN1478467A (zh) | 口腔内快速崩解片剂及其制备方法 | |
CN1698618A (zh) | 青蒿琥酯与盐酸阿莫地喹双层片及其制备方法 | |
CN1076966C (zh) | 大黄素在制备延缓慢性肾衰的药物中的应用 | |
CN1634587A (zh) | 一种增效治疗急、慢性肝病的复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ANHUI BIOLOGICAL MEDICAL SCIENCE INST. Effective date: 20120713 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120713 Address after: 4103 box 230038, Anhui University of Traditional Chinese Medicine, Mount Mei Road, Shushan District, Anhui, Hefei Co-patentee after: Anhui Biological Medical Institute Patentee after: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER Address before: 4103 box 230038, Anhui University of Traditional Chinese Medicine, Mount Mei Road, Shushan District, Anhui, Hefei Patentee before: Anhui Modern Chinese Medicine Research Center |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ANHUI BIOLOGICAL MEDICAL SCIENCE INST. Effective date: 20130328 Owner name: BEIJING AOSA MEDICINE RESEARCH CENTRE CO., LTD. Free format text: FORMER OWNER: ANHUI MODERN CHINESE MEDICINE RESEARCH CENTER Effective date: 20130328 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Guangliang Inventor after: Xu Xiping Inventor after: Wang Linlin Inventor after: Duan Yanyan Inventor after: Liu Haipeng Inventor after: Li Li Inventor after: Wang Binyan Inventor before: Chen Guangliang Inventor before: Wang Linlin Inventor before: Duan Yanyan Inventor before: Liu Haipeng Inventor before: Li Li |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN GUANGLIANG WANG LINLIN DUAN YANYAN LIU HAIPENG LI LI TO: CHEN GUANGLIANG XU XIPING WANG LINLIN DUAN YANYAN LIU HAIPENG LI LI WANG BINYAN Free format text: CORRECT: ADDRESS; FROM: 230038 HEFEI, ANHUI PROVINCE TO: 100176 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130328 Address after: 100176, No. 18 West South Road, Beijing economic and Technological Development Zone, C512 Patentee after: Beijng Aosa Medical Research Center, Inc. Address before: 4103 box 230038, Anhui University of Traditional Chinese Medicine, Mount Mei Road, Shushan District, Anhui, Hefei Patentee before: Anhui Modern Chinese Medicine Research Center Patentee before: Anhui Biological Medical Institute |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition containing insulin sensibilizer and B-family vatamines Effective date of registration: 20130523 Granted publication date: 20110706 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: Beijng Aosa Medical Research Center, Inc. Registration number: 2013990000309 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20110706 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: Beijng Aosa Medical Research Center, Inc. Registration number: 2013990000309 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000309 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 100176 Beijing economic and Technological Development Zone, West Beijing Road, No. 18, block C, room 216 Patentee after: Beijng Aosa Medical Research Center, Inc. Address before: 100176 No. 18 West South Road, Beijing economic and Technological Development Zone, C512 Patentee before: Beijng Aosa Medical Research Center, Inc. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201030 Address after: 246000 No.11 Xiaogushan Road, economic development zone, Anqing City, Anhui Province Patentee after: Anqing research center of Anhui Biomedical Research Institute Address before: 100176 Beijing economic and Technological Development Zone, West Beijing Road, No. 18, block C, room 216 Patentee before: Beijng Aosa Medical Research Center, Inc. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230309 Address after: 518000 The 1st and 2nd floors of Building 2, Phase III, Biological Incubator, No. 16, High-tech Middle Road, High-tech Zone, Nanshan District, Shenzhen, Guangdong Province; East side of 1st floor, 2nd and 3rd floors of Building 3 Patentee after: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Anqing research center of Anhui Biomedical Research Institute Address before: 246000 No.11, Xiaogushan Road, Jingkai District, Anqing City, Anhui Province Patentee before: Anqing research center of Anhui Biomedical Research Institute |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 518000 The 1st and 2nd floors of Building 2, Phase III, Biological Incubator, No. 16, High-tech Middle Road, High-tech Zone, Nanshan District, Shenzhen, Guangdong Province; East side of 1st floor, 2nd and 3rd floors of Building 3 Patentee after: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Anqing Changqing Medical Research Institute Address before: 518000 The 1st and 2nd floors of Building 2, Phase III, Biological Incubator, No. 16, High-tech Middle Road, High-tech Zone, Nanshan District, Shenzhen, Guangdong Province; East side of 1st floor, 2nd and 3rd floors of Building 3 Patentee before: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee before: Anqing research center of Anhui Biomedical Research Institute |